Kexing Biopharm Co., Ltd. (SHA:688136)

Market Cap	3.99B -45.4%
Revenue (ttm)	1.46B +4.4%
Net Income	112.05M +150.9%
EPS	0.57 +149.3%
Shares Out	197.86M
PE Ratio	35.58
Forward PE	32.55
Dividend	0.25 (1.18%)
Ex-Dividend Date	n/a

Volume	3,795,193
Open	21.00
Previous Close	21.11
Day's Range	19.95 - 21.01
52-Week Range	19.95 - 63.99
Beta	0.33
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 21, 2026

About Kexing Biopharm

Kexing Biopharm Co., Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of recombinant protein drugs and microecological preparations in China, the European Union, Brazil, the Philippines, and Indonesia. The company focuses on oncology, immunology, and degenerative diseases; and develops new antibodies, proteins, nucleic acid drugs, and antiviral therapy, as well as for the treatment of tumor, autoimmune, metabolic diseases, and other therapeutic fields. It also develops GB05 human interferon a1b in...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 1,048
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688136

Financial Performance

In 2025, Kexing Biopharm's revenue was 1.53 billion, an increase of 9.03% compared to the previous year's 1.41 billion. Earnings were 155.57 million, an increase of 394.17%.